Cambridge University Hospitals
Cambridge University Hospitals (CUH) is one of the largest and best known hospitals in the country, delivering high-quality patient care through Addenbrooke’s and the Rosie Hospitals. CUH is a leading national centre for specialist treatment for rare or complex conditions and a university teaching hospital with a worldwide reputation.
CUH is a key partner in Cambridge University Health Partners (CUHP), one of only six academic health science centres in the UK, and is at the heart of the development of the Cambridge Biomedical Campus (CBC), which brings together on one site world-class biomedical research, patient care and education. As part of the Campus development, Papworth Hospital is creating a bespoke, purpose-built hospital, and AstraZeneca is building a new global R&D centre and corporate headquarters. The Campus is one of the government’s 11 National Institute for Health Research (NIHR) comprehensive biomedical research centres.
The Trust already works closely with a number of research partners across the Campus, for example, the Medical Research Council (MRC), Cancer Research UK (CRUK), the University of Cambridge and The Wellcome Trust, to develop new drugs and new therapies to improve treatment and patient care.http://www.cuh.org.uk/
Founded in 1209, the University comprises 31 autonomous Colleges, which admit undergraduates and provide small-group tuition, and 150 departments, faculties and institutions.
Cambridge is a global university. Its 19,000 student body includes 3,700 international students from 120 countries. Cambridge researchers collaborate with colleagues worldwide, and the University has established larger-scale partnerships in Asia, Africa and America.
The University sits at the heart of one of the world’s largest technology clusters. The ‘Cambridge Phenomenon’ has created 1,500 hi-tech companies, 14 of them valued at over US$1 billion and two at over US$10 billion. Cambridge promotes the interface between academia and business, and has a global reputation for innovation.
AstraZeneca and MedImmune
We are a global, science-led biopharmaceutical business, headquartered on the Cambridge Biomedical Campus, and our innovative medicines are used by millions of patients worldwide. Our major focus is to develop medicines for Oncology, Respiratory, Inflammation and Autoimmunity, and Cardiovascular and Metabolic diseases, with an opportunity-driven approach to Infection, Neuroscience and Gastrointestinal diseases.
Our two R&D biotech units, MedImmune and IMED, use novel science and innovation in biologics, small molecules, immunotherapies, protein engineering and devices, to provide candidate medicines for our late-stage development unit.
By co-locating our R&D next to world leading bioscience clusters in Cambridge, UK; Gaithersburg, Maryland, US; and Gothenburg, Sweden, we can collaborate with leading scientists and research organisations.
We have extensive research collaborations with our neighbours on the Campus including with the hospital and University departments and partner institutions.
By inspiring and organising collaboration, CUHP aims to ensure patients reap the benefits of the world class research, clinicians and industry which are based in Cambridge and the surrounding area.
We are at the forefront of the changing face of medicine and healthcare as researchers and doctors look to treat patients by understanding the mechanisms of disease rather than simply treat the symptoms.
This means various fields of science are collaborating as physicists, mathematicians and engineers are now working with clinicians to develop new and more effective treatments. Cambridge, with its rich history of research and innovation, is ideally placed to be the global leader in healthcare.
Cancer Research UK Cambridge Centre
The Cancer Research UK Cambridge Centre unites more than 600 laboratory researchers and healthcare professionals in more than 24 University Departments, nine world-leading research institutions, two NHS Foundation Trusts (Cambridge University Hospitals and Royal Papworth Hospital) and four major pharmaceutical companies sited across the wider Cambridge area.
Our mission is to end death and disease caused by cancer, through research, treatment and education. As one of just two Cancer Research UK Major Centres, we serve as a national and international resource for patients with cancer and their families; researchers and health care providers; and cancer professionals in training.
The Cancer Research UK Cambridge Centre facilitates new collaborations and drives the translation of new scientific discoveries into clinical applications to improve patient care. By working together across a range of different disciplines, our members are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.
Collaboration for Leadership in Applied Health Research & Care (CLAHRC)
We are a collaboration of academics, clinicians and managers who undertake high quality applied health research focused on the needs of patients and service users, supporting the translation of research evidence into practice in the NHS and social care.
NIHR CLAHRC East of England focuses its research efforts on the needs of people with complex problems, often vulnerable when multiple agencies are involved in their care: young people, frail older people, those with dementia, learning disabilities, acquired brain injuries or mental ill health.
The CLAHRC collaboration encompasses some thirty-six organisations, with research hubs in the Universities of Cambridge, Hertfordshire and East Anglia working closely with individuals and organisations involved in the whole care pathway.
Eastern Academic Health Science Network
Eastern Academic Health Science Network is one of 15 Academic Health Science Networks (AHSNs) set up to spread innovation at pace and scale across the healthcare system – in order to achieve the ultimate goals of both improving health and generating economic growth.
Innovation is our business. We have deep rooted knowledge of the academic, industry and NHS sectors, and the challenges of diffusing best practice and innovation.
Our regional focus ensures that we are grounded in the specific context of our local populations and clinical communities. We understand their challenges and are able to translate innovations to achieve better health outcomes at pace and scale.
We don’t work alone. The strength of our partnerships uniquely positions us to connect diverse bodies from across the health and care system enabling us to successfully co-create solutions to achieve better patient outcomes.
At EMBL-EBI, we perform basic research in bioinformatics, make the world’s public biological data freely available to the scientific community via a range of services and tools, and provide professional training in bioinformatics.
Innovative early phase 1 and 2 studies are designed, set up and executed using the principles of experimental medicine. Scientists and clinicians are trained and interact to support the scientific knowledge and advance innovative and experimental clinical trial design in GSK. Our position on the campus has enabled us to develop a large number of academic links and collaborations to support and conduct experimental and translational studies and to recruit patients by partnering with the local networks as well as in the wider environment.
MRC Biostatistics Unit
The Medical Research Council (MRC) has had a statistical unit since its inception in 1913. One hundred years on, the MRC Biostatistics Unit (BSU), is one of the largest groups of biostatisticians in Europe. It is a major centre for research, training and knowledge transfer, with a mission 'to advance biomedical science and human health through the development, application and dissemination of statistical methods'.
BSU’s critical mass of methodological, applied and computational expertise provides a unique and stimulating environment of cutting edge biostatistics, striking a balance between statistical innovation, dissemination of methodology, and engagement with biomedical and public health priorities.
BSU is based at the Cambridge Institute of Public Health at the Forvie Site, and since December 2016 is part of the School of Clinical Medicine at the University of Cambridge.
The LMB has made revolutionary contributions to science, such as pioneering the sequencing of DNA and the development of monoclonal antibodies. Ten Nobel Prizes have been awarded for work carried out by our scientists.
Since 2013 the LMB has occupied a purpose-built, £212 million facility on the Cambridge Biomedical Campus, providing an unsurpassed environment for both young and established researchers, with state-of-the-art facilities and a unique scientific culture. The LMB has always been very diverse, with a truly international outlook – we currently employ more than 600 staff from over 50 countries.
RDS advisers offer a unique breadth of experience in helping both novice and more experienced researchers to develop competitive research applications. Advice is confidential and free of charge.
If you are developing a research proposal to attract NIHR/other National competitive funding, please complete the RDS client enquiry form on the RDS East of England website. An adviser will contact you to set up an initial meeting to talk through your research ideas and to get an understanding of why the research is important. As the grant application evolves, advisers will provide on-going advice on the study design and methods, and will help to ensure that the research team has the required expertise. They will signpost you to the relevant departments and organisations that you will need to liaise with when developing a competitive application. The RDS holds regular bid development workshops and also offers ‘pre-submission’ panels.